Faecal microbiota transplantation for recurrent C. difficile in cats
Recurrent Clostridioides difficile infection (rCDI) causes repeated bouts of diarrhoea, sometimes vomiting, abdominal pain and weight loss in cats. It can follow antimicrobial treatment, hospitalisation or major stress, and may resemble inflammatory bowel disease, parasitic infection or dietary disease. Fecal microbiota transplantation (FMT) aims to restore microbial balance by transferring carefully screened donor faeces into the recipient’s gastrointestinal tract.
Evidence in cats is promising but limited. Most clinical knowledge comes from small case series, experimental work and guidance extrapolated from human medicine, so FMT should not be presented as an established replacement for antimicrobial therapy. Its value is greatest when recurrent disease has been thoroughly investigated, obvious triggers have been addressed and an experienced veterinary team can monitor the response.
Why recurrence changes the clinical picture
A feline rCDI case is usually more complex than a single positive faecal test. Repeated clinical signs, recent antimicrobial exposure and compatible findings should be considered together, because many healthy cats carry C. difficile without toxin-mediated illness. There is also no universally accepted feline definition of recurrence, making a clear treatment timeline and owner history particularly important.
Antibiotics may remove competing organisms and reduce microbial stability, while stress, poor nutrition and hospitalisation can compound the problem. In Australia, clinicians may hear owners describe a “sore tummy” or “kitty’s gut” acting up, yet these phrases cover several different diagnoses. A structured history, hydration assessment and nutrition review are therefore as valuable as the initial laboratory result.
Confirming the disease before FMT
Before transferring microbiota, clinicians should document active diarrhoea and investigate competing causes. Testing may include faecal toxin assays, culture or polymerase chain reaction for toxigenic C. difficile, plus targeted screens for parasites such as Giardia and Tritrichomonas foetus. Imaging, abdominal ultrasound or gastrointestinal sampling may be needed when disease is severe or atypical.
A positive polymerase chain reaction identifies organisms but does not, by itself, prove that toxins are causing the current signs. Results should be interpreted alongside clinical severity, serial testing and prior treatments. This distinction helps prevent FMT being used unnecessarily or delaying care for a condition such as lymphoma, feline inflammatory bowel disease or a foreign body.
What FMT can and cannot achieve
FMT seeks to re-establish colonisation resistance: a diverse microbial community that makes the gut less hospitable to overgrowth. In selected cats, clinical improvement has been reported after donor material is introduced, sometimes when standard supportive management has not prevented further episodes. The exact microbial “healthy” profile is not yet defined, and transferring material does not repair structural intestinal damage or remove every predisposing factor.
Current feline evidence does not support firm predictions about success rate, optimal dose or number of treatments. Some animals respond quickly, while others need additional investigation or different management. FMT should therefore be framed as a supervised, adjunctive option with uncertain benefit, not a guaranteed cure or a reason to stop prescribed care. Probiotics alone are not an equivalent substitute because their composition and delivery differ from a screened faecal preparation.
Screening donors and handling faeces safely
Donor selection is a clinical and biosafety decision. Donor cats should have normal faecal consistency and no recent gastrointestinal illness, and both animals and donors may require screening for enteric pathogens, parasites and antimicrobial-resistance genes. Identity, collection date and storage history must be traceable, while preparing and transporting material under conditions that preserve anaerobic organisms.
Australia’s geography and warm climate make these controls practical challenges. A clinic in Sydney, Melbourne, Brisbane or Perth may have access to specialist laboratory support, whereas a regional practice could depend on couriers and overnight freight, with cold-chain validation and a documented contingency for delayed samples. Dedicated feline donor banks appear more limited here than in some overseas markets, so many services may need carefully governed local arrangements.
Clinicians seeking wider microbiome education can review expert webinars and downloadable resources through Hills ActivBiome support. Such educational material should complement, rather than replace, a case-specific protocol, donor assessment, informed consent and strict infection-control procedures.
Delivering treatment and tracking response
The route must suit the cat and the preparation. Oral administration may use a syringe or feeding tube, while rectal delivery requires careful restraint and, in some settings, sedation or anaesthesia. Both approaches carry risks: oral delivery can provoke aspiration or regurgitation, and rectal administration can cause stress or trauma. FMT should not be attempted at home without a veterinary-directed protocol.
Monitoring should focus on stool consistency, appetite, hydration, body weight and recurrence frequency, with the understanding that improvement may take days rather than hours. Repeated toxin testing after apparent recovery is not always useful because carriage can persist, and treatment should not be based on a single negative result. Any renewed diarrhoea warrants reassessment for infection, dietary relapse, parasites or other enteropathies.
Owners need a realistic explanation of costs, uncertain evidence and possible repeat procedures. Written discharge advice should include feeding, medication adherence, warning signs and a clear contact pathway. A follow-up appointment should be scheduled before discharge, particularly if the cat was hospitalised or has other chronic conditions.
Building a responsible Australian clinical pathway
An Australian service should clarify the regulatory status of each preparation before use. Veterinary compounded preparations, imported biological products and fresh donor material may be governed by different requirements, with oversight from the Australian Veterinary Medicines Authority as well as state and territory veterinary authorities. Practice owners should document their governance, waste handling, traceability and informed-consent process rather than assuming human FMT rules apply directly.
Access also depends on procurement and staffing. A small practice may partner with a university veterinary hospital or referral centre, while a larger hospital could maintain its own screening and preparation workflow. Because companion-animal care does not attract a Pharmaceutical Benefits Scheme subsidy, clinics should provide written estimates and advise owners to check their policy: pet insurance may exclude experimental, chronic or investigational treatment.
A sustainable pathway combines microbiome specialists, diagnostic laboratories, pharmacists or compounding chemists, veterinary nurses and client-service staff. It should review each case for avoidable antimicrobial exposure, nutrition and infection-control gaps, then audit clinical outcomes and adverse events. For recurrent feline C. difficile infection, FMT is most defensible when used selectively, within a regulated veterinary system and with outcomes measured honestly rather than presented as a quick fix.